Product Description: Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a potent and orally active nucleoside antitumor agent. The composition of Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-tri-fluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). Trifluridine/tipiracil hydrochloride mixture (TAS-102) shows the antitumor activity mainly via the inhibition of thymidylate synthase (TS) and incorporation into DNA[1][2].
Applications: Cancer-programmed cell death
Formula: C10H11F3N2O5.1/2C9H11ClN4O2.1/2HCl
References: [1]Emura T, et al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med. 2004;13(4):545-549./[2]Nukatsuka M, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res. 2015;35(3):1437-1445./[3]Limagne E, Thibaudin M, Nuttin L, et al. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages. Cancer Immunol Res. 2019;7(12):1958-1969. /[4]Suzuki N, Nakagawa F, Takechi T. Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer [published correction appears in Oncol Lett. 2021 Jul;22(1):511]. Oncol Lett. 2017;14(1):639-646.
CAS Number: 733030-01-8
Molecular Weight: 435.76
Compound Purity: 99.98
Research Area: Cancer
Solubility: DMF : 20 mg/mL (ultrasonic)/DMSO : 2.34 mg/mL (ultrasonic;warming)/H2O : 100 mg/mL (ultrasonic)
Target: Nucleoside Antimetabolite/Analog;Thymidylate Synthase
English
Deutsch
